Glucocorticoid exposure remains a major contributor to morbidity and mortality in patients with immune-mediated kidney disease. Recent clinical trials have tested novel potential therapies for these patients and showed that glucocorticoid doses can be reduced without compromising efficacy.
Key advances
-
C5a receptor antagonism with avacopan is effective in combination with cyclophosphamide or rituximab for inducing and maintaining remission in severe anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and reduces glucocorticoid requirements.
-
Reducing glucocorticoid dose with rituximab for the induction of remission in AAV does not compromise short-term efficacy and reduces serious infections.
-
Use of the calcineurin inhibitor voclosporin with mycophenolate mofetil (MMF) and glucocorticoids improves renal response in patients with class III–V lupus nephritis and eGFR >45 ml/min/1.73 m2.
-
Obinutuzumab combined with MMF and glucocorticoids increases renal response in patients with class III–IV lupus nephitis.
-
Inhibition of sodium–glucose co-transporter 2 with dapagliflozin in proteinuric IgA nephropathy improves renal outcomes.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jayne, D. R. W., Merkel, P. A., Schall, T. J. & Bekker, P. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599–609 (2021).
Walsh, M. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622–631 (2020).
Furuta, S. et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. J. Am. Med. Assoc. 325, 2178–2187 (2021).
Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070–2080 (2021).
Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2021-220920 (2021).
Rauen, T. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 373, 2225–2236 (2015).
Lv, J. et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. J. Am. Med. Assoc. 318, 432–442 (2017).
Wheeler, D. C. et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 100, 215–224 (2021).
Barratt, J. & Floege, J. SGLT-2 inhibition in IgA nephropathy: the new standard of care? Kidney Int. 100, 24–26 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.K. has received consultancy fees from Vifor Pharma, Alexion, Otsuka and Catalyst Biosciences. R.B.J. has received grants from GSK and Roche, and has consulted for Chemocentryx, Vifor Pharma and GSK.
Rights and permissions
About this article
Cite this article
Kronbichler, A., Jones, R.B. Improving outcomes in glomerular disease. Nat Rev Nephrol 18, 82–83 (2022). https://doi.org/10.1038/s41581-021-00526-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-021-00526-z